Advertisement
The Genous stent is coated with an antibody to capture a patient'sendothelial progenitor cells (EPCs) circulating in the bloodstream. Whenattracted to the inner surface of the Genous stent, EPCs have been shown toquickly form a healthy layer of endothelium that minimizes stent restenosisand provides protection against stent thrombosis.
Advertisement
"We are pleased to be able to offer the Genous stent to interventionalcardiologists in Taiwan," said Teddy Chien, OrbusNeich's chairman. "Theintroduction of our pro-healing stent to the Taiwanese market is an importantstep for our company as we expand our presence in the Asia-Pacific region.Based on our interaction with Taiwanese physicians, we expect strong Genoussales from the outset because of the demand for safe alternatives todrug-eluting stents."
An estimated 20,000 coronary angioplasty procedures will be performed inTaiwan in 2008, 60% of which are expected to involve the use of drug elutingor coated stents.
"We are pleased to have Genous stents become available in Taiwan," saidJui-Sung Hung, M.D., FACC, FAHA, founding President of the Taiwan Society ofCardiovascular Interventions. "Preliminary studies have shown that the use ofGenous stents is as safe and effective as TAXUS DES, and more importantly,that the stent thrombosis rate at 12 months is lower with the Genous stentdespite one month of dual antiplatelet therapy. Although results oflarge-scale, randomized control trials are awaited to make more definitiveconclusions, I believe Genous will be a good treatment option for patients whocannot undergo long-term dual antiplatelet therapy or patients who haveincreased risk of thrombotic events."
OrbusNeich designs, develops, manufactures and markets innovative medicaldevices for the treatment of vascular diseases. The company's productportfolio includes the Genous Bio-engineered R stent, an antibody-coateddevice that is the first-ever stent to capture a patient's endothelialprogenitor cells (EPCs) to accelerate the natural healing process followingplacement. Other products are stents, balloons and guiding catheters marketedunder the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), AvitaHP(TM), SafeCut(TM), Lumina(TM) and Saffron.
As a global company, OrbusNeich is headquartered in Hong Kong and hasoperations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; andShenzhen, China. OrbusNeich, which has provided cardiology devices tophysicians through its predecessor companies since 1979, today suppliesproducts to interventional cardiologists in more than 60 countries. For moreinformation, visit www.OrbusNeich.com.
SOURCE OrbusNeich
